Knut Elbers

Knut is Director of the Boehringer Ingelheim Corporate Venture Fund. Over the last three years, he has been involved in several investments of the fund. He served as board member of Okarios AG in Basel having had a successful exit in 2013. He is also board member of NBE Therapeutics in Basel since 2013 and of Amal Therapeutics in Geneva since 2014. His scientific strength especially in the field of immunotherapy and NBE technologies is resulting in strategic input in the Venture Fund strategy in this specific focus space.

Knut joined Boehringer Ingelheim in 1995 in the international research and development department of the animal health business. From 1999 to 2008 he was heading the European vaccine research organization for animal health. Subsequently he collected experiences in human antibody related research and development being involved in R&D project management and Collaborative Research for NBEs.

During his work at Boehringer Ingelheim Knut was involved in 12 patent applications and key development projects like (Ingelvac PRRSV, Enterisol Ileitis, Ingelvac CircoFLEX) contributing significantly to the vaccine business success of the animal health business of Boehringer Ingelheim.

Knut has studied biology at the Eberhard-Karls-University in Tübingen with specific focus on virology and immunology. He performed his Ph.D. work at
the federal institute for viral diseases in Tübingen focusing on protein processing during viral replication and pathogen/host interaction mechanism.

Dr. Knut Elbers

Knut Elbers

Contact Venture Fund